+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Oral Antiparkinsonian Drugs Market - Global Forecast 2026-2032- Product Image
Oral Antiparkinsonian Drugs Market - Global Forecast 2026-2032- Product Image
Sale

Oral Antiparkinsonian Drugs Market - Global Forecast 2026-2032

  • Report

  • 187 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6143438
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Oral Antiparkinsonian Drugs Market is projected to reach USD 10.60 Billion in 2026. It is expected to continue growing at a CAGR of 9.01%, reaching USD 17.71 Billion by 2032.

Oral Antiparkinsonian Drugs: Executive Summary

Oral antiparkinsonian drugs remain an important component of Parkinson’s disease management, supporting symptom control through dopaminergic, dopamine-modulating, anticholinergic, and adjunctive treatment approaches. Clinical use is shaped by disease stage, motor and non-motor symptoms, comorbidities, tolerability, adherence, and access to specialist care. Treatment decisions increasingly emphasize individualized sequencing, sustained symptom control, and management of complications associated with long-term therapy.

Treatment Is Shifting Toward Individualized, Long-Term Care

The treatment landscape is changing from a primarily symptom-focused model toward integrated, longitudinal management. Earlier attention to personalized dosing, motor fluctuations, dyskinesia, sleep disturbance, cognitive symptoms, autonomic dysfunction, and psychiatric effects is influencing oral therapy selection. Clinicians are also balancing efficacy with risks such as hallucinations, impulse-control disorders, nausea, orthostatic hypotension, sedation, and cognitive impairment. These shifts reinforce the need for coordinated neurology, primary care, pharmacy, rehabilitation, and caregiver support.

Artificial Intelligence Strengthens Diagnosis, Monitoring, and Treatment Support

Artificial intelligence is contributing to Parkinson’s disease care through movement analysis, speech assessment, digital symptom tracking, clinical documentation, and identification of patterns that may support earlier referral or treatment adjustment. Its most practical near-term value is likely to come from combining patient-reported outcomes, wearable signals, medication records, and clinician judgment. Validation across diverse populations remains essential, particularly because algorithmic performance can vary by device, language, disease stage, disability, and access to digital tools. AI should support-not replace-clinical assessment and shared decision-making.

Regional Differences Reflect Access, Diagnosis, and Care-Infrastructure Gaps

North America benefits from established specialist networks, broad clinical research activity, and growing use of digital monitoring, although affordability and unequal access remain important concerns. Europe combines mature healthcare systems with country-level differences in reimbursement, referral pathways, and specialist availability. Asia-Pacific presents substantial variation, with advanced neurological services in markets such as Japan, South Korea, and Australia alongside access constraints in other settings. Latin America faces uneven diagnosis, medicine availability, and specialist coverage. The Middle East shows concentrated centers of expertise and differing reimbursement environments, while Africa continues to experience major gaps in neurological workforce capacity, diagnostic access, and continuity of treatment. Across all regions, reliable supply, affordable therapy, and caregiver education are central to better outcomes.

Economic and Institutional Groups Shape Medicine Access Differently

Within ASEAN, variation in healthcare financing, specialist density, and medicine procurement creates uneven access to diagnosis and oral treatment. BRICS countries span highly diverse public and private systems, with domestic production, reimbursement policy, and urban-rural disparities influencing continuity of care. The European Union benefits from collaborative regulatory and health-policy structures but retains substantial differences in national reimbursement and service delivery. G7 members generally have stronger specialist capacity and pharmacovigilance systems, while aging populations and treatment affordability remain relevant pressures. NATO countries share some infrastructure and research links, yet access and care pathways differ considerably. GCC states often combine advanced urban facilities with workforce-dependence and geographic access challenges, making coordinated referral and long-term follow-up important.

Country Contexts Highlight Distinct Priorities for Oral Therapy

Australia and Canada must address geographic dispersion and specialist access, while the United States continues to balance innovation and specialist care with affordability and insurance complexity. Brazil, Mexico, India, China, and Russia face pronounced regional differences in diagnosis, treatment continuity, and neurological workforce distribution. Japan, South Korea, Germany, France, Italy, Spain, and the United Kingdom have comparatively developed clinical systems, but each must manage aging populations, service capacity, reimbursement differences, and long-term care coordination. Across these countries, improving timely diagnosis, medication adherence, caregiver support, and access to multidisciplinary services can strengthen the impact of oral antiparkinsonian treatment.

Prioritize Access, Safety, Adherence, and Data-Enabled Care

Industry leaders should support evidence-based education that helps clinicians and patients recognize treatment benefits, adverse effects, adherence barriers, and symptom progression. Supply planning should prioritize dependable availability and practical access across urban and underserved settings. Partnerships with healthcare providers can strengthen medication review, caregiver training, and referral to rehabilitation and specialist services. Digital and AI-enabled tools should be developed with transparent validation, privacy safeguards, interoperability, and inclusion of underrepresented populations. Evidence generation should focus on real-world persistence, quality of life, non-motor symptoms, treatment complications, and outcomes across different healthcare systems.

Methodology Combines Clinical, Policy, and Geographic Evidence

This executive summary uses a structured qualitative synthesis of established clinical principles, healthcare-access considerations, treatment-safety themes, digital-health developments, and the specified regional, group, and country frameworks. The assessment emphasizes verifiable patterns relevant to oral antiparkinsonian therapy, including disease-management needs, care delivery, reimbursement context, specialist capacity, and technology adoption. It excludes market estimates, market sizing, market shares, forecasts, and company-specific analysis. Conclusions should be interpreted alongside current clinical guidelines, regulatory information, local reimbursement rules, and country-level epidemiological evidence.

Coordinated, Personalized Care Will Define the Next Phase

Oral antiparkinsonian drugs will remain central to Parkinson’s disease management, but their value increasingly depends on how effectively they are integrated into personalized, multidisciplinary, and continuous care. Regional and country differences make flexible access strategies essential. Leaders who combine treatment quality with safety monitoring, adherence support, equitable distribution, validated digital tools, and stronger clinical coordination will be better positioned to improve patient-centered outcomes without relying on a one-size-fits-all model.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Oral Antiparkinsonian Drugs Market, by Class
7.1. Introduction
7.2. Anticholinergic Agents
7.2.1. Benztropine
7.2.2. Trihexyphenidyl
7.3. Comt Inhibitors
7.3.1. Entacapone
7.3.2. Opicapone
7.3.3. Tolcapone
7.4. Dopamine Agonists
7.4.1. Pramipexole
7.4.2. Ropinirole
7.4.3. Rotigotine
7.5. Levodopa
7.5.1. Carbidopa-Levodopa
7.5.2. Levodopa-Entacapone
7.5.3. Levodopa-Opicapone
7.6. Mao-B Inhibitors
7.6.1. Rasagiline
7.6.2. Selegiline
8. Oral Antiparkinsonian Drugs Market, by Product Type
8.1. Introduction
8.2. Branded
8.2.1. Azilect
8.2.2. Mirapex
8.2.3. Requip
8.2.4. Rytary
8.2.5. Sinemet
8.3. Generic
8.3.1. Carbidopa-Levodopa Generic
8.3.2. Entacapone Generic
8.3.3. Pramipexole Generic
8.3.4. Rasagiline Generic
8.3.5. Ropinirole Generic
9. Oral Antiparkinsonian Drugs Market, by Formulation
9.1. Introduction
9.2. Controlled Release
9.2.1. Capsules
9.2.2. Tablets
9.3. Immediate Release
9.3.1. Capsules
9.3.2. Tablets
10. Oral Antiparkinsonian Drugs Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacies
10.3. Online Pharmacies
10.4. Retail Pharmacies
11. Oral Antiparkinsonian Drugs Market, by Therapy
11.1. Introduction
11.2. Adjunct Therapy
11.3. Monotherapy
12. Oral Antiparkinsonian Drugs Market, by Region
12.1. Introduction
12.2. Asia-Pacific
12.3. North America
12.4. Latin America
12.5. Europe
12.6. Middle East
12.7. Africa
13. Oral Antiparkinsonian Drugs Market, by Group
13.1. Introduction
13.2. ASEAN
13.3. GCC
13.4. European Union
13.5. BRICS
13.6. G7
13.7. NATO
14. Oral Antiparkinsonian Drugs Market, by Country
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. United Kingdom
14.7. Germany
14.8. France
14.9. Russia
14.10. Italy
14.11. Spain
14.12. China
14.13. India
14.14. Japan
14.15. Australia
14.16. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. Market Concentration Analysis, 2025
15.2.1. Concentration Ratio (CR)
15.2.2. Herfindahl Hirschman Index (HHI)
15.3. Recent Developments & Impact Analysis, 2025
15.4. Product Portfolio Analysis, 2025
15.5. Benchmarking Analysis, 2025
16. Company Profiles
16.1. AbbVie Inc.
16.2. Boehringer Ingelheim International GmbH
16.3. Cipla Ltd.
16.4. Dr. Reddy’s Laboratories Ltd.
16.5. GlaxoSmithKline plc
16.6. Intas Pharmaceuticals Ltd.
16.7. Merck & Co., Inc.
16.8. Mylan NV
16.9. Neurocrine Biosciences Inc.
16.10. Novartis AG
16.11. Orion Pharma Ltd.
16.12. Sandoz International GmbH
16.13. Sun Pharmaceutical Industries Ltd.
16.14. Supernus Pharmaceuticals Inc.
16.15. Teva Pharmaceutical Industries Ltd.
16.16. Upsher-Smith Laboratories LLC
16.17. US WorldMeds LLC
16.18. Viatris Inc.
16.19. Wockhardt Ltd.
16.20. Zydus Lifesciences Limited
17. Key Experts
LIST OF FIGURES
FIGURE 1. Global Oral Antiparkinsonian Drugs Market, Years Considered for the Study
FIGURE 2. Global Oral Antiparkinsonian Drugs Market, Research Design
FIGURE 3. Global Oral Antiparkinsonian Drugs Market, Research Framework
FIGURE 4. Global Oral Antiparkinsonian Drugs Market, Data Triangulation
FIGURE 5. Global Oral Antiparkinsonian Drugs Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Oral Antiparkinsonian Drugs Market Size, by Class, 2025 vs 2032 (%)
FIGURE 7. Global Oral Antiparkinsonian Drugs Market Size, by Class, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Oral Antiparkinsonian Drugs Market Size, by Product Type, 2025 vs 2032 (%)
FIGURE 9. Global Oral Antiparkinsonian Drugs Market Size, by Product Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Oral Antiparkinsonian Drugs Market Size, by Formulation, 2025 vs 2032 (%)
FIGURE 11. Global Oral Antiparkinsonian Drugs Market Size, by Formulation, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Oral Antiparkinsonian Drugs Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 13. Global Oral Antiparkinsonian Drugs Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Oral Antiparkinsonian Drugs Market Size, by Therapy, 2025 vs 2032 (%)
FIGURE 15. Global Oral Antiparkinsonian Drugs Market Size, by Therapy, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Oral Antiparkinsonian Drugs Market Size, by Region, 2025 vs 2032 (%)
FIGURE 17. Global Oral Antiparkinsonian Drugs Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Oral Antiparkinsonian Drugs Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Oral Antiparkinsonian Drugs Market Size, by Country, 2025 vs 2032 (%)
FIGURE 20. Global Oral Antiparkinsonian Drugs Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global Oral Antiparkinsonian Drugs Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Oral Antiparkinsonian Drugs Market Segmentation & Coverage
TABLE 2. Global Oral Antiparkinsonian Drugs Market Size, 2017-2032 (USD Million)
TABLE 3. Global Oral Antiparkinsonian Drugs Market Size, by Class, 2017-2032 (USD Million)
TABLE 4. Global Anticholinergic Agents Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Anticholinergic Agents Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Anticholinergic Agents Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Benztropine Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Benztropine Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Benztropine Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Trihexyphenidyl Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Trihexyphenidyl Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Trihexyphenidyl Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Comt Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Comt Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Comt Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Entacapone Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Entacapone Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Entacapone Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Opicapone Market Size, by Region, 2017-2032 (USD Million)
TABLE 20. Global Opicapone Market Size, by Group, 2017-2032 (USD Million)
TABLE 21. Global Opicapone Market Size, by Country, 2017-2032 (USD Million)
TABLE 22. Global Tolcapone Market Size, by Region, 2017-2032 (USD Million)
TABLE 23. Global Tolcapone Market Size, by Group, 2017-2032 (USD Million)
TABLE 24. Global Tolcapone Market Size, by Country, 2017-2032 (USD Million)
TABLE 25. Global Dopamine Agonists Market Size, by Region, 2017-2032 (USD Million)
TABLE 26. Global Dopamine Agonists Market Size, by Group, 2017-2032 (USD Million)
TABLE 27. Global Dopamine Agonists Market Size, by Country, 2017-2032 (USD Million)
TABLE 28. Global Pramipexole Market Size, by Region, 2017-2032 (USD Million)
TABLE 29. Global Pramipexole Market Size, by Group, 2017-2032 (USD Million)
TABLE 30. Global Pramipexole Market Size, by Country, 2017-2032 (USD Million)
TABLE 31. Global Ropinirole Market Size, by Region, 2017-2032 (USD Million)
TABLE 32. Global Ropinirole Market Size, by Group, 2017-2032 (USD Million)
TABLE 33. Global Ropinirole Market Size, by Country, 2017-2032 (USD Million)
TABLE 34. Global Rotigotine Market Size, by Region, 2017-2032 (USD Million)
TABLE 35. Global Rotigotine Market Size, by Group, 2017-2032 (USD Million)
TABLE 36. Global Rotigotine Market Size, by Country, 2017-2032 (USD Million)
TABLE 37. Global Levodopa Market Size, by Region, 2017-2032 (USD Million)
TABLE 38. Global Levodopa Market Size, by Group, 2017-2032 (USD Million)
TABLE 39. Global Levodopa Market Size, by Country, 2017-2032 (USD Million)
TABLE 40. Global Carbidopa-Levodopa Market Size, by Region, 2017-2032 (USD Million)
TABLE 41. Global Carbidopa-Levodopa Market Size, by Group, 2017-2032 (USD Million)
TABLE 42. Global Carbidopa-Levodopa Market Size, by Country, 2017-2032 (USD Million)
TABLE 43. Global Levodopa-Entacapone Market Size, by Region, 2017-2032 (USD Million)
TABLE 44. Global Levodopa-Entacapone Market Size, by Group, 2017-2032 (USD Million)
TABLE 45. Global Levodopa-Entacapone Market Size, by Country, 2017-2032 (USD Million)
TABLE 46. Global Levodopa-Opicapone Market Size, by Region, 2017-2032 (USD Million)
TABLE 47. Global Levodopa-Opicapone Market Size, by Group, 2017-2032 (USD Million)
TABLE 48. Global Levodopa-Opicapone Market Size, by Country, 2017-2032 (USD Million)
TABLE 49. Global Mao-B Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 50. Global Mao-B Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 51. Global Mao-B Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 52. Global Rasagiline Market Size, by Region, 2017-2032 (USD Million)
TABLE 53. Global Rasagiline Market Size, by Group, 2017-2032 (USD Million)
TABLE 54. Global Rasagiline Market Size, by Country, 2017-2032 (USD Million)
TABLE 55. Global Selegiline Market Size, by Region, 2017-2032 (USD Million)
TABLE 56. Global Selegiline Market Size, by Group, 2017-2032 (USD Million)
TABLE 57. Global Selegiline Market Size, by Country, 2017-2032 (USD Million)
TABLE 58. Global Oral Antiparkinsonian Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 59. Global Branded Market Size, by Region, 2017-2032 (USD Million)
TABLE 60. Global Branded Market Size, by Group, 2017-2032 (USD Million)
TABLE 61. Global Branded Market Size, by Country, 2017-2032 (USD Million)
TABLE 62. Global Azilect Market Size, by Region, 2017-2032 (USD Million)
TABLE 63. Global Azilect Market Size, by Group, 2017-2032 (USD Million)
TABLE 64. Global Azilect Market Size, by Country, 2017-2032 (USD Million)
TABLE 65. Global Mirapex Market Size, by Region, 2017-2032 (USD Million)
TABLE 66. Global Mirapex Market Size, by Group, 2017-2032 (USD Million)
TABLE 67. Global Mirapex Market Size, by Country, 2017-2032 (USD Million)
TABLE 68. Global Requip Market Size, by Region, 2017-2032 (USD Million)
TABLE 69. Global Requip Market Size, by Group, 2017-2032 (USD Million)
TABLE 70. Global Requip Market Size, by Country, 2017-2032 (USD Million)
TABLE 71. Global Rytary Market Size, by Region, 2017-2032 (USD Million)
TABLE 72. Global Rytary Market Size, by Group, 2017-2032 (USD Million)
TABLE 73. Global Rytary Market Size, by Country, 2017-2032 (USD Million)
TABLE 74. Global Sinemet Market Size, by Region, 2017-2032 (USD Million)
TABLE 75. Global Sinemet Market Size, by Group, 2017-2032 (USD Million)
TABLE 76. Global Sinemet Market Size, by Country, 2017-2032 (USD Million)
TABLE 77. Global Generic Market Size, by Region, 2017-2032 (USD Million)
TABLE 78. Global Generic Market Size, by Group, 2017-2032 (USD Million)
TABLE 79. Global Generic Market Size, by Country, 2017-2032 (USD Million)
TABLE 80. Global Carbidopa-Levodopa Generic Market Size, by Region, 2017-2032 (USD Million)
TABLE 81. Global Carbidopa-Levodopa Generic Market Size, by Group, 2017-2032 (USD Million)
TABLE 82. Global Carbidopa-Levodopa Generic Market Size, by Country, 2017-2032 (USD Million)
TABLE 83. Global Entacapone Generic Market Size, by Region, 2017-2032 (USD Million)
TABLE 84. Global Entacapone Generic Market Size, by Group, 2017-2032 (USD Million)
TABLE 85. Global Entacapone Generic Market Size, by Country, 2017-2032 (USD Million)
TABLE 86. Global Pramipexole Generic Market Size, by Region, 2017-2032 (USD Million)
TABLE 87. Global Pramipexole Generic Market Size, by Group, 2017-2032 (USD Million)
TABLE 88. Global Pramipexole Generic Market Size, by Country, 2017-2032 (USD Million)
TABLE 89. Global Rasagiline Generic Market Size, by Region, 2017-2032 (USD Million)
TABLE 90. Global Rasagiline Generic Market Size, by Group, 2017-2032 (USD Million)
TABLE 91. Global Rasagiline Generic Market Size, by Country, 2017-2032 (USD Million)
TABLE 92. Global Ropinirole Generic Market Size, by Region, 2017-2032 (USD Million)
TABLE 93. Global Ropinirole Generic Market Size, by Group, 2017-2032 (USD Million)
TABLE 94. Global Ropinirole Generic Market Size, by Country, 2017-2032 (USD Million)
TABLE 95. Global Oral Antiparkinsonian Drugs Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 96. Global Controlled Release Market Size, by Region, 2017-2032 (USD Million)
TABLE 97. Global Controlled Release Market Size, by Group, 2017-2032 (USD Million)
TABLE 98. Global Controlled Release Market Size, by Country, 2017-2032 (USD Million)
TABLE 99. Global Capsules Market Size, by Region, 2017-2032 (USD Million)
TABLE 100. Global Capsules Market Size, by Group, 2017-2032 (USD Million)
TABLE 101. Global Capsules Market Size, by Country, 2017-2032 (USD Million)
TABLE 102. Global Tablets Market Size, by Region, 2017-2032 (USD Million)
TABLE 103. Global Tablets Market Size, by Group, 2017-2032 (USD Million)
TABLE 104. Global Tablets Market Size, by Country, 2017-2032 (USD Million)
TABLE 105. Global Immediate Release Market Size, by Region, 2017-2032 (USD Million)
TABLE 106. Global Immediate Release Market Size, by Group, 2017-2032 (USD Million)
TABLE 107. Global Immediate Release Market Size, by Country, 2017-2032 (USD Million)
TABLE 108. Global Capsules Market Size, by Region, 2017-2032 (USD Million)
TABLE 109. Global Capsules Market Size, by Group, 2017-2032 (USD Million)
TABLE 110. Global Capsules Market Size, by Country, 2017-2032 (USD Million)
TABLE 111. Global Tablets Market Size, by Region, 2017-2032 (USD Million)
TABLE 112. Global Tablets Market Size, by Group, 2017-2032 (USD Million)
TABLE 113. Global Tablets Market Size, by Country, 2017-2032 (USD Million)
TABLE 114. Global Oral Antiparkinsonian Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 115. Global Hospital Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 116. Global Hospital Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 117. Global Hospital Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 118. Global Online Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 119. Global Online Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 120. Global Online Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 121. Global Retail Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 122. Global Retail Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 123. Global Retail Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 124. Global Oral Antiparkinsonian Drugs Market Size, by Therapy, 2017-2032 (USD Million)
TABLE 125. Global Adjunct Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 126. Global Adjunct Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 127. Global Adjunct Therapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 128. Global Monotherapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 129. Global Monotherapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 130. Global Monotherapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 131. Global Oral Antiparkinsonian Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 132. Asia-Pacific Oral Antiparkinsonian Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 133. Asia-Pacific Oral Antiparkinsonian Drugs Market Size, by Class, 2017-2032 (USD Million)
TABLE 134. Asia-Pacific Oral Antiparkinsonian Drugs Market Size, by Anticholinergic Agents, 2017-2032 (USD Million)
TABLE 135. Asia-Pacific Oral Antiparkinsonian Drugs Market Size, by Comt Inhibitors, 2017-2032 (USD Million)
TABLE 136. Asia-Pacific Oral Antiparkinsonian Drugs Market Size, by Dopamine Agonists, 2017-2032 (USD Million)
TABLE 137. Asia-Pacific Oral Antiparkinsonian Drugs Market Size, by Levodopa, 2017-2032 (USD Million)
TABLE 138. Asia-Pacific Oral Antiparkinsonian Drugs Market Size, by Mao-B Inhibitors, 2017-2032 (USD Million)
TABLE 139. Asia-Pacific Oral Antiparkinsonian Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 140. Asia-Pacific Oral Antiparkinsonian Drugs Market Size, by Branded, 2017-2032 (USD Million)
TABLE 141. Asia-Pacific Oral Antiparkinsonian Drugs Market Size, by Generic, 2017-2032 (USD Million)
TABLE 142. Asia-Pacific Oral Antiparkinsonian Drugs Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 143. Asia-Pacific Oral Antiparkinsonian Drugs Market Size, by Controlled Release, 2017-2032 (USD Million)
TABLE 144. Asia-Pacific Oral Antiparkinsonian Drugs Market Size, by Immediate Release, 2017-2032 (USD Million)
TABLE 145. Asia-Pacific Oral Antiparkinsonian Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 146. Asia-Pacific Oral Antiparkinsonian Drugs Market Size, by Therapy, 2017-2032 (USD Million)
TABLE 147. North America Oral Antiparkinsonian Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 148. North America Oral Antiparkinsonian Drugs Market Size, by Class, 2017-2032 (USD Million)
TABLE 149. North America Oral Antiparkinsonian Drugs Market Size, by Anticholinergic Agents, 2017-2032 (USD Million)
TABLE 150. North America Oral Antiparkinsonian Drugs Market Size, by Comt Inhibitors, 2017-2032 (USD Million)
TABLE 151. North America Oral Antiparkinsonian Drugs Market Size, by Dopamine Agonists, 2017-2032 (USD Million)
TABLE 152. North America Oral Antiparkinsonian Drugs Market Size, by Levodopa, 2017-2032 (USD Million)
TABLE 153. North America Oral Antiparkinsonian Drugs Market Size, by Mao-B Inhibitors, 2017-2032 (USD Million)
TABLE 154. North America Oral Antiparkinsonian Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 155. North America Oral Antiparkinsonian Drugs Market Size, by Branded, 2017-2032 (USD Million)
TABLE 156. North America Oral Antiparkinsonian Drugs Market Size, by Generic, 2017-2032 (USD Million)
TABLE 157. North America Oral Antiparkinsonian Drugs Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 158. North America Oral Antiparkinsonian Drugs Market Size, by Controlled Release, 2017-2032 (USD Million)
TABLE 159. North America Oral Antiparkinsonian Drugs Market Size, by Immediate Release, 2017-2032 (USD Million)
TABLE 160. North America Oral Antiparkinsonian Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 161. North America Oral Antiparkinsonian Drugs Market Size, by Therapy, 2017-2032 (USD Million)
TABLE 162. Latin America Oral Antiparkinsonian Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 163. Latin America Oral Antiparkinsonian Drugs Market Size, by Class, 2017-2032 (USD Million)
TABLE 164. Latin America Oral Antiparkinsonian Drugs Market Size, by Anticholinergic Agents, 2017-2032 (USD Million)
TABLE 165. Latin America Oral Antiparkinsonian Drugs Market Size, by Comt Inhibitors, 2017-2032 (USD Million)
TABLE 166. Latin America Oral Antiparkinsonian Drugs Market Size, by Dopamine Agonists, 2017-2032 (USD Million)
TABLE 167. Latin America Oral Antiparkinsonian Drugs Market Size, by Levodopa, 2017-2032 (USD Million)
TABLE 168. Latin America Oral Antiparkinsonian Drugs Market Size, by Mao-B Inhibitors, 2017-2032 (USD Million)
TABLE 169. Latin America Oral Antiparkinsonian Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 170. Latin America Oral Antiparkinsonian Drugs Market Size, by Branded, 2017-2032 (USD Million)
TABLE 171. Latin America Oral Antiparkinsonian Drugs Market Size, by Generic, 2017-2032 (USD Million)
TABLE 172. Latin America Oral Antiparkinsonian Drugs Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 173. Latin America Oral Antiparkinsonian Drugs Market Size, by Controlled Release, 2017-2032 (USD Million)
TABLE 174. Latin America Oral Antiparkinsonian Drugs Market Size, by Immediate Release, 2017-2032 (USD Million)
TABLE 175. Latin America Oral Antiparkinsonian Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 176. Latin America Oral Antiparkinsonian Drugs Market Size, by Therapy, 2017-2032 (USD Million)
TABLE 177. Europe Oral Antiparkinsonian Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 178. Europe Oral Antiparkinsonian Drugs Market Size, by Class, 2017-2032 (USD Million)
TABLE 179. Europe Oral Antiparkinsonian Drugs Market Size, by Anticholinergic Agents, 2017-2032 (USD Million)
TABLE 180. Europe Oral Antiparkinsonian Drugs Market Size, by Comt Inhibitors, 2017-2032 (USD Million)
TABLE 181. Europe Oral Antiparkinsonian Drugs Market Size, by Dopamine Agonists, 2017-2032 (USD Million)
TABLE 182. Europe Oral Antiparkinsonian Drugs Market Size, by Levodopa, 2017-2032 (USD Million)
TABLE 183. Europe Oral Antiparkinsonian Drugs Market Size, by Mao-B Inhibitors, 2017-2032 (USD Million)
TABLE 184. Europe Oral Antiparkinsonian Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 185. Europe Oral Antiparkinsonian Drugs Market Size, by Branded, 2017-2032 (USD Million)
TABLE 186. Europe Oral Antiparkinsonian Drugs Market Size, by Generic, 2017-2032 (USD Million)
TABLE 187. Europe Oral Antiparkinsonian Drugs Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 188. Europe Oral Antiparkinsonian Drugs Market Size, by Controlled Release, 2017-2032 (USD Million)
TABLE 189. Europe Oral Antiparkinsonian Drugs Market Size, by Immediate Release, 2017-2032 (USD Million)
TABLE 190. Europe Oral Antiparkinsonian Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 191. Europe Oral Antiparkinsonian Drugs Market Size, by Therapy, 2017-2032 (USD Million)
TABLE 192. Middle East Oral Antiparkinsonian Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 193. Middle East Oral Antiparkinsonian Drugs Market Size, by Class, 2017-2032 (USD Million)
TABLE 194. Middle East Oral Antiparkinsonian Drugs Market Size, by Anticholinergic Agents, 2017-2032 (USD Million)
TABLE 195. Middle East Oral Antiparkinsonian Drugs Market Size, by Comt Inhibitors, 2017-2032 (USD Million)
TABLE 196. Middle East Oral Antiparkinsonian Drugs Market Size, by Dopamine Agonists, 2017-2032 (USD Million)
TABLE 197. Middle East Oral Antiparkinsonian Drugs Market Size, by Levodopa, 2017-2032 (USD Million)
TABLE 198. Middle East Oral Antiparkinsonian Drugs Market Size, by Mao-B Inhibitors, 2017-2032 (USD Million)
TABLE 199. Middle East Oral Antiparkinsonian Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 200. Middle East Oral Antiparkinsonian Drugs Market Size, by Branded, 2017-2032 (USD Million)
TABLE 201. Middle East Oral Antiparkinsonian Drugs Market Size, by Generic, 2017-2032 (USD Million)
TABLE 202. Middle East Oral Antiparkinsonian Drugs Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 203. Middle East Oral Antiparkinsonian Drugs Market Size, by Controlled Release, 2017-2032 (USD Million)
TABLE 204. Middle East Oral Antiparkinsonian Drugs Market Size, by Immediate Release, 2017-2032 (USD Million)
TABLE 205. Middle East Oral Antiparkinsonian Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 206. Middle East Oral Antiparkinsonian Drugs Market Size, by Therapy, 2017-2032 (USD Million)
TABLE 207. Africa Oral Antiparkinsonian Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 208. Africa Oral Antiparkinsonian Drugs Market Size, by Class, 2017-2032 (USD Million)
TABLE 209. Africa Oral Antiparkinsonian Drugs Market Size, by Anticholinergic Agents, 2017-2032 (USD Million)
TABLE 210. Africa Oral Antiparkinsonian Drugs Market Size, by Comt Inhibitors, 2017-2032 (USD Million)
TABLE 211. Africa Oral Antiparkinsonian Drugs Market Size, by Dopamine Agonists, 2017-2032 (USD Million)
TABLE 212. Africa Oral Antiparkinsonian Drugs Market Size, by Levodopa, 2017-2032 (USD Million)
TABLE 213. Africa Oral Antiparkinsonian Drugs Market Size, by Mao-B Inhibitors, 2017-2032 (USD Million)
TABLE 214. Africa Oral Antiparkinsonian Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 215. Africa Oral Antiparkinsonian Drugs Market Size, by Branded, 2017-2032 (USD Million)
TABLE 216. Africa Oral Antiparkinsonian Drugs Market Size, by Generic, 2017-2032 (USD Million)
TABLE 217. Africa Oral Antiparkinsonian Drugs Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 218. Africa Oral Antiparkinsonian Drugs Market Size, by Controlled Release, 2017-2032 (USD Million)
TABLE 219. Africa Oral Antiparkinsonian Drugs Market Size, by Immediate Release, 2017-2032 (USD Million)
TABLE 220. Africa Oral Antiparkinsonian Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 221. Africa Oral Antiparkinsonian Drugs Market Size, by Therapy, 2017-2032 (USD Million)
TABLE 222. Global Oral Antiparkinsonian Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 223. ASEAN Oral Antiparkinsonian Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 224. ASEAN Oral Antiparkinsonian Drugs Market Size, by Class, 2017-2032 (USD Million)
TABLE 225. ASEAN Oral Antiparkinsonian Drugs Market Size, by Anticholinergic Agents, 2017-2032 (USD Million)
TABLE 226. ASEAN Oral Antiparkinsonian Drugs Market Size, by Comt Inhibitors, 2017-2032 (USD Million)
TABLE 227. ASEAN Oral Antiparkinsonian Drugs Market Size, by Dopamine Agonists, 2017-2032 (USD Million)
TABLE 228. ASEAN Oral Antiparkinsonian Drugs Market Size, by Levodopa, 2017-2032 (USD Million)
TABLE 229. ASEAN Oral Antiparkinsonian Drugs Market Size, by Mao-B Inhibitors, 2017-2032 (USD Million)
TABLE 230. ASEAN Oral Antiparkinsonian Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 231. ASEAN Oral Antiparkinsonian Drugs Market Size, by Branded, 2017-2032 (USD Million)
TABLE 232. ASEAN Oral Antiparkinsonian Drugs Market Size, by Generic, 2017-2032 (USD Million)
TABLE 233. ASEAN Oral Antiparkinsonian Drugs Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 234. ASEAN Oral Antiparkinsonian Drugs Market Size, by Controlled Release, 2017-2032 (USD Million)
TABLE 235. ASEAN Oral Antiparkinsonian Drugs Market Size, by Immediate Release, 2017-2032 (USD Million)
TABLE 236. ASEAN Oral Antiparkinsonian Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 237. ASEAN Oral Antiparkinsonian Drugs Market Size, by Therapy, 2017-2032 (USD Million)
TABLE 238. GCC Oral Antiparkinsonian Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 239. GCC Oral Antiparkinsonian Drugs Market Size, by Class, 2017-2032 (USD Million)
TABLE 240. GCC Oral Antiparkinsonian Drugs Market Size, by Anticholinergic Agents, 2017-2032 (USD Million)
TABLE 241. GCC Oral Antiparkinsonian Drugs Market Size, by Comt Inhibitors, 2017-2032 (USD Million)
TABLE 242. GCC Oral Antiparkinsonian Drugs Market Size, by Dopamine Agonists, 2017-2032 (USD Million)
TABLE 243. GCC Oral Antiparkinsonian Drugs Market Size, by Levodopa, 2017-2032 (USD Million)
TABLE 244. GCC Oral Antiparkinsonian Drugs Market Size, by Mao-B Inhibitors, 2017-2032 (USD Million)
TABLE 245. GCC Oral Antiparkinsonian Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 246. GCC Oral Antiparkinsonian Drugs Market Size, by Branded, 2017-2032 (USD Million)
TABLE 247. GCC Oral Antiparkinsonian Drugs Market Size, by Generic, 2017-2032 (USD Million)
TABLE 248. GCC Oral Antiparkinsonian Drugs Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 249. GCC Oral Antiparkinsonian Drugs Market Size, by Controlled Release, 2017-2032 (USD Million)
TABLE 250. GCC Oral Antiparkinsonian Drugs Market Size, by Immediate Release, 2017-2032 (USD Million)
TABLE 251. GCC Oral Antiparkinsonian Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 252. GCC Oral Antiparkinsonian Drugs Market Size, by Therapy, 2017-2032 (USD Million)
TABLE 253. European Union Oral Antiparkinsonian Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 254. European Union Oral Antiparkinsonian Drugs Market Size, by Class, 2017-2032 (USD Million)
TABLE 255. European Union Oral Antiparkinsonian Drugs Market Size, by Anticholinergic Agents, 2017-2032 (USD Million)
TABLE 256. European Union Oral Antiparkinsonian Drugs Market Size, by Comt Inhibitors, 2017-2032 (USD Million)
TABLE 257. European Union Oral Antiparkinsonian Drugs Market Size, by Dopamine Agonists, 2017-2032 (USD Million)
TABLE 258. European Union Oral Antiparkinsonian Drugs Market Size, by Levodopa, 2017-2032 (USD Million)
TABLE 259. European Union Oral Antiparkinsonian Drugs Market Size, by Mao-B Inhibitors, 2017-2032 (USD Million)
TABLE 260. European Union Oral Antiparkinsonian Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 261. European Union Oral Antiparkinsonian Drugs Market Size, by Branded, 2017-2032 (USD Million)
TABLE 262. European Union Oral Antiparkinsonian Drugs Market Size, by Generic, 2017-2032 (USD Million)
TABLE 263. European Union Oral Antiparkinsonian Drugs Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 264. European Union Oral Antiparkinsonian Drugs Market Size, by Controlled Release, 2017-2032 (USD Million)
TABLE 265. European Union Oral Antiparkinsonian Drugs Market Size, by Immediate Release, 2017-2032 (USD Million)
TABLE 266. European Union Oral Antiparkinsonian Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 267. European Union Oral Antiparkinsonian Drugs Market Size, by Therapy, 2017-2032 (USD Million)
TABLE 268. BRICS Oral Antiparkinsonian Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 269. BRICS Oral Antiparkinsonian Drugs Market Size, by Class, 2017-2032 (USD Million)
TABLE 270. BRICS Oral Antiparkinsonian Drugs Market Size, by Anticholinergic Agents, 2017-2032 (USD Million)
TABLE 271. BRICS Oral Antiparkinsonian Drugs Market Size, by Comt Inhibitors, 2017-2032 (USD Million)
TABLE 272. BRICS Oral Antiparkinsonian Drugs Market Size, by Dopamine Agonists, 2017-2032 (USD Million)
TABLE 273. BRICS Oral Antiparkinsonian Drugs Market Size, by Levodopa, 2017-2032 (USD Million)
TABLE 274. BRICS Oral Antiparkinsonian Drugs Market Size, by Mao-B Inhibitors, 2017-2032 (USD Million)
TABLE 275. BRICS Oral Antiparkinsonian Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 276. BRICS Oral Antiparkinsonian Drugs Market Size, by Branded, 2017-2032 (USD Million)
TABLE 277. BRICS Oral Antiparkinsonian Drugs Market Size, by Generic, 2017-2032 (USD Million)
TABLE 278. BRICS Oral Antiparkinsonian Drugs Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 279. BRICS Oral Antiparkinsonian Drugs Market Size, by Controlled Release, 2017-2032 (USD Million)
TABLE 280. BRICS Oral Antiparkinsonian Drugs Market Size, by Immediate Release, 2017-2032 (USD Million)
TABLE 281. BRICS Oral Antiparkinsonian Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 282. BRICS Oral Antiparkinsonian Drugs Market Size, by Therapy, 2017-2032 (USD Million)
TABLE 283. G7 Oral Antiparkinsonian Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 284. G7 Oral Antiparkinsonian Drugs Market Size, by Class, 2017-2032 (USD Million)
TABLE 285. G7 Oral Antiparkinsonian Drugs Market Size, by Anticholinergic Agents, 2017-2032 (USD Million)
TABLE 286. G7 Oral Antiparkinsonian Drugs Market Size, by Comt Inhibitors, 2017-2032 (USD Million)
TABLE 287. G7 Oral Antiparkinsonian Drugs Market Size, by Dopamine Agonists, 2017-2032 (USD Million)
TABLE 288. G7 Oral Antiparkinsonian Drugs Market Size, by Levodopa, 2017-2032 (USD Million)
TABLE 289. G7 Oral Antiparkinsonian Drugs Market Size, by Mao-B Inhibitors, 2017-2032 (USD Million)
TABLE 290. G7 Oral Antiparkinsonian Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 291. G7 Oral Antiparkinsonian Drugs Market Size, by Branded, 2017-2032 (USD Million)
TABLE 292. G7 Oral Antiparkinsonian Drugs Market Size, by Generic, 2017-2032 (USD Million)
TABLE 293. G7 Oral Antiparkinsonian Drugs Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 294. G7 Oral Antiparkinsonian Drugs Market Size, by Controlled Release, 2017-2032 (USD Million)
TABLE 295. G7 Oral Antiparkinsonian Drugs Market Size, by Immediate Release, 2017-2032 (USD Million)
TABLE 296. G7 Oral Antiparkinsonian Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 297. G7 Oral Antiparkinsonian Drugs Market Size, by Therapy, 2017-2032 (USD Million)
TABLE 298. NATO Oral Antiparkinsonian Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 299. NATO Oral Antiparkinsonian Drugs Market Size, by Class, 2017-2032 (USD Million)
TABLE 300. NATO Oral Antiparkinsonian Drugs Market Size, by Anticholinergic Agents, 2017-2032 (USD Million)
TABLE 301. NATO Oral Antiparkinsonian Drugs Market Size, by Comt Inhibitors, 2017-2032 (USD Million)
TABLE 302. NATO Oral Antiparkinsonian Drugs Market Size, by Dopamine Agonists, 2017-2032 (USD Million)
TABLE 303. NATO Oral Antiparkinsonian Drugs Market Size, by Levodopa, 2017-2032 (USD Million)
TABLE 304. NATO Oral Antiparkinsonian Drugs Market Size, by Mao-B Inhibitors, 2017-2032 (USD Million)
TABLE 305. NATO Oral Antiparkinsonian Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 306. NATO Oral Antiparkinsonian Drugs Market Size, by Branded, 2017-2032 (USD Million)
TABLE 307. NATO Oral Antiparkinsonian Drugs Market Size, by Generic, 2017-2032 (USD Million)
TABLE 308. NATO Oral Antiparkinsonian Drugs Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 309. NATO Oral Antiparkinsonian Drugs Market Size, by Controlled Release, 2017-2032 (USD Million)
TABLE 310. NATO Oral Antiparkinsonian Drugs Market Size, by Immediate Release, 2017-2032 (USD Million)
TABLE 311. NATO Oral Antiparkinsonian Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 312. NATO Oral Antiparkinsonian Drugs Market Size, by Therapy, 2017-2032 (USD Million)
TABLE 313. Global Oral Antiparkinsonian Drugs Market Size, by Country, 2017-2032 (USD Million)
TABLE 314. United States Oral Antiparkinsonian Drugs Market Size, 2017-2032 (USD Million)
TABLE 315. United States Oral Antiparkinsonian Drugs Market Size, by Class, 2017-2032 (USD Million)
TABLE 316. United States Oral Antiparkinsonian Drugs Market Size, by Anticholinergic Agents, 2017-2032 (USD Million)
TABLE 317. United States Oral Antiparkinsonian Drugs Market Size, by Comt Inhibitors, 2017-2032 (USD Million)
TABLE 318. United States Oral Antiparkinsonian Drugs Market Size, by Dopamine Agonists, 2017-2032 (USD Million)
TABLE 319. United States Oral Antiparkinsonian Drugs Market Size, by Levodopa, 2017-2032 (USD Million)
TABLE 320. United States Oral Antiparkinsonian Drugs Market Size, by Mao-B Inhibitors, 2017-2032 (USD Million)
TABLE 321. United States Oral Antiparkinsonian Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 322. United States Oral Antiparkinsonian Drugs Market Size, by Branded, 2017-2032 (USD Million)
TABLE 323. United States Oral Antiparkinsonian Drugs Market Size, by Generic, 2017-2032 (USD Million)
TABLE 324. United States Oral Antiparkinsonian Drugs Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 325. United States Oral Antiparkinsonian Drugs Market Size, by Controlled Release, 2017-2032 (USD Million)
TABLE 326. United States Oral Antiparkinsonian Drugs Market Size, by Immediate Release, 2017-2032 (USD Million)
TABLE 327. United States Oral Antiparkinsonian Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 328. United States Oral Antiparkinsonian Drugs Market Size, by Therapy, 2017-2032 (USD Million)
TABLE 329. Canada Oral Antiparkinsonian Drugs Market Size, 2017-2032 (USD Million)
TABLE 330. Canada Oral Antiparkinsonian Drugs Market Size, by Class, 2017-2032 (USD Million)
TABLE 331. Canada Oral Antiparkinsonian Drugs Market Size, by Anticholinergic Agents, 2017-2032 (USD Million)
TABLE 332. Canada Oral Antiparkinsonian Drugs Market Size, by Comt Inhibitors, 2017-2032 (USD Million)
TABLE 333. Canada Oral Antiparkinsonian Drugs Market Size, by Dopamine Agonists, 2017-2032 (USD Million)
TABLE 334. Canada Oral Antiparkinsonian Drugs Market Size, by Levodopa, 2017-2032 (USD Million)
TABLE 335. Canada Oral Antiparkinsonian Drugs Market Size, by Mao-B Inhibitors, 2017-2032 (USD Million)
TABLE 336. Canada Oral Antiparkinsonian Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 337. Canada Oral Antiparkinsonian Drugs Market Size, by Branded, 2017-2032 (USD Million)
TABLE 338. Canada Oral Antiparkinsonian Drugs Market Size, by Generic, 2017-2032 (USD Million)
TABLE 339. Canada Oral Antiparkinsonian Drugs Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 340. Canada Oral Antiparkinsonian Drugs Market Size, by Controlled Release, 2017-2032 (USD Million)
TABLE 341. Canada Oral Antiparkinsonian Drugs Market Size, by Immediate Release, 2017-2032 (USD Million)
TABLE 342. Canada Oral Antiparkinsonian Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 343. Canada Oral Antiparkinsonian Drugs Market Size, by Therapy, 2017-2032 (USD Million)
TABLE 344. Mexico Oral Antiparkinsonian Drugs Market Size, 2017-2032 (USD Million)
TABLE 345. Mexico Oral Antiparkinsonian Drugs Market Size, by Class, 2017-2032 (USD Million)
TABLE 346. Mexico Oral Antiparkinsonian Drugs Market Size, by Anticholinergic Agents, 2017-2032 (USD Million)
TABLE 347. Mexico Oral Antiparkinsonian Drugs Market Size, by Comt Inhibitors, 2017-2032 (USD Million)
TABLE 348. Mexico Oral Antiparkinsonian Drugs Market Size, by Dopamine Agonists, 2017-2032 (USD Million)
TABLE 349. Mexico Oral Antiparkinsonian Drugs Market Size, by Levodopa, 2017-2032 (USD Million)
TA

Companies Mentioned

  • AbbVie Inc.
  • Boehringer Ingelheim International GmbH
  • Cipla Ltd.
  • Dr. Reddy’s Laboratories Ltd.
  • GlaxoSmithKline plc
  • Intas Pharmaceuticals Ltd.
  • Merck & Co., Inc.
  • Mylan NV
  • Neurocrine Biosciences Inc.
  • Novartis AG
  • Orion Pharma Ltd.
  • Sandoz International GmbH
  • Sun Pharmaceutical Industries Ltd.
  • Supernus Pharmaceuticals Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Upsher‑Smith Laboratories LLC
  • US WorldMeds LLC
  • Viatris Inc.
  • Wockhardt Ltd.
  • Zydus Lifesciences Limited

Related Topics

Related Reports

Incontinence Medication Market - Global Forecast 2026-2032 - Product Image

Incontinence Medication Market - Global Forecast 2026-2032

  • Report
  • 188 Pages
  • Global
From
Calcium Homeostatic Drugs Market - Global Forecast 2026-2032 - Product Image

Calcium Homeostatic Drugs Market - Global Forecast 2026-2032

  • Report
  • 180 Pages
  • Global
From
Pharmerging - Global Strategic Business Report - Product Image

Pharmerging - Global Strategic Business Report

  • Report
  • 198 Pages
  • Global
From
GLP-1 Therapies - Market Insights, Competitive Landscape, and Market Forecast - 2034 - Product Image

GLP-1 Therapies - Market Insights, Competitive Landscape, and Market Forecast - 2034

  • Report
  • 150 Pages
  • Global
From
Vitamin D Therapy - Global Strategic Business Report - Product Image

Vitamin D Therapy - Global Strategic Business Report

  • Report
  • 222 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.